Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of its Annual Report on Form 20-F. The filing was issued on March 8, 2022, and covers the audited financial statements for the fiscal year ended December 31, 2021.
Key Financial Metrics
The provided text does not contain specific financial data. It acts solely as a cover document announcing the availability of the full Annual Report. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text.
Material Changes
No material changes or comparative financial data are disclosed in this specific document. The filing references the full 2021 Annual Report for detailed financial performance and year-over-year comparisons.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being detailed under Item 3.D "Risk factors" in the 2021 Annual Report on Form 20-F. No specific guidance or management commentary on future performance is included in this text.
Investor Verification Checklist
- Verify the full audited financial statements in the 2021 Annual Report on Form 20-F available at www.gsk.com/corporatereporting or www.sec.gov.
- Review Item 3.D "Risk factors" in the Form 20-F for detailed disclosures on uncertainties affecting forward-looking statements.
- Confirm the availability of hard copies of the financial statements and the Notice of Annual General Meeting, expected on or about March 28, 2022.
- Check contact details for Equiniti Limited (UK registrar) or J.P. Morgan Chase Bank, N.A. (US ADR depositary) for shareholder services.